Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P495 Usefulness of a capsule endoscopy scoring system in understanding the disease state of Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

T. Omori, H. Kambayashi, S. Murasugi, A. Ito, M. Yonezawa, K. Tokushige

Institute of Gastroenterology, Tokyo Women’s Medical University, Tokyo, Japan

P496 Feasibility and safety of single incision laparoscopic surgery for patients with complex Crohn’s disease

ECCO'20 Vienna

Year: 2020
Authors:

Y. LI, B. Liu, D. Yao, L. Zheng, Z. Zhou, Y. Huang, Y. Duan

Department of Surgery, Shanghai Ninth People’s Hospital -Shanghai Jiaotong University School, Shanghai, China

P497 Is mucosal healing sufficient paramater for anti-TNF discontinuation?

ECCO'20 Vienna

Year: 2020
Authors:

T. Knezevic1, M. Milic2, A. Kalaba1, S. Sreckovic1, B. Stopic3, P. Svorcan1, S. Markovic1

1Department of Gastroenterology and Hepatology, University Hospital Medical Center ‘ Zvezdara’, Belgrade, Serbia, 2Department of Pathology, University Hospital Medical Center ‘ Zvezdara’, Belgrade, Serbia, 3Department of Nephrology, University Hospital Medical Center ‘ Zvezdara’, Belgrade, Serbia

P498 Loss of response of anti-TNF in Crohn’s disease patients single-centre experience

ECCO'20 Vienna

Year: 2020
Authors:

A. Atanassova, A.C. Georgieva, M. Mirchev

Medical University – Varna- Bulgaria, University Hospital St. Marina- Clinic of Gastroenterology, Varna, Bulgaria

P499 Objectively assessed disease activity during ustekinumab treatment in a nationwide real-life Crohn’s disease cohort

ECCO'20 Vienna

Year: 2020
Authors:

C.G. af Björkesten1, T. Ilus2, T. Hallinen3, E. Soini3, A. Eberl1, K. Hakala4, M. Heikura5, E. Hirsi6, A. Jussila2, M. Kellokumpu7, R. Koskela8, I. Koskinen9, V. Moilanen10, C. Nielsen11, U. Nieminen1, H. Nuutinen12, M. Heikkinen13, U.M. Suhonen14, J. Tillonen15, K. Utriainen16, I. Vihriälä17, C. Wennerström18,19, A. Borsi20, R. Nissinen21, M. Koivunen21, T. Sipponen1

1University of Helsinki and Helsinki University Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 2Tampere University Hospital, Tampere University Hospital, Tampere, Finland, 3ESiOR Oy, ESiOR Oy, Kuopio, Finland, 4Kanta-Häme Central Hospital, Kanta-Häme Central Hospital, Hämeenlinna, Finland, 5North Karelia Central Hospital, North Karelia Central Hospital, Joensuu, Finland, 6South Karelia Central Hospital, South Karelia Central Hospital, Lappeenranta, Finland, 7Lapland Central Hospital, Lapland Central Hospital, Rovaniemi, Finland, 8Oulu University Hospital, Oulu University Hospital, Oulu, Finland, 9Central Finland Central Hospital, Central Finland Central Hospital, Jyväskylä, Finland, 10Satakunta Central Hospital, Satakunta Central Hospital, Pori, Finland, 11Vaasa Central Hospital, Vaasa Central Hospital, Vaasa, Finland, 12Turku University Hospital, Turku University Hospital, Turku, Finland, 13Kuopio University Hospital, Kuopio University Hospital, Kuopio, Finland, 14Kainuu Central Hospital, Kainuu Central Hospital, Kajaani, Finland, 15Päijät-Häme Central Hospital, Päijät-Häme Central Hospital, Lahti, Finland, 16Turku University Hospital- Salo Hospital, Turku University Hospital- Salo Hospital, Salo, Finland, 17Central Ostrobothnia Central Hospital, Central Ostrobothnia Central Hospital, Kokkola, Finland, 18Janssen Cilag AB, Medical Affairs, Solna, Sweden, 19Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, 20Janssen Cilag Limited, emea hemar, High Wycombe, UK, 21Janssen Cilag Oy, Medical Affairs, Espoo, Finland

P500 Adiposity among IBD patients

ECCO'20 Vienna

Year: 2020
Authors:

M. Bletsa1, A. Karachaliou2, G. Kokkotis3, M.M. Tsoutska1, S. Andoniadi2, I. Papaconstantinou4, M. Kontogianni2, G. Bamias3

1Nutrition and Dietetic Department, Sotiria General Hospital, Athens, Greece, 2Department of Nutrition and Dietetics, Harokopio University, Athens, Greece, 3GI Unit- 3rd Department of Internal Medicine, Sotiria General Hospital, Athens, Greece, 42nd Department of Surgery, Aretaieion Hospital, Athens, Greece

P501 Thiopurine withdrawal in patients with Crohn’s disease: the SURESTE study

ECCO'20 Vienna

Year: 2020
Authors:

E. Sánchez Rodríguez1, R. Sánchez Aldehuelo1, J. Guardiola2, A. Gutiérrez Casbas3, E. Domènech4, F. Bermejo5, M. Van-Domselaar6, F. Mesonero Gismero1, G. Suris2, R. Muñoz Perez3, M. Mañosa4, L. Jiménez Márquez5, A. Algaba García5, A. López sanroman1, SURESTE

1Hospital Universitario Ramón y Cajal, Servicio de Gastroenterologia y Hepatología, Madrid, Spain, 2Hospital Universitari de Bellvitge, Servicio de Aparato Digestivo, Barcelona, Spain, 3Hospital General Universitario de Alicante, Servicio Medicina Digestiva, alicante, Spain, 4Hospital Universitari Germans Trias i Pujol, Servicio de Aparato Digestivo, Badalona, Spain, 5Hospital Universitario de Fuenlabrada, Servicio de Aparato Digestivo, madrid, Spain, 6Hospital Universitario de Torrejón., Servicio de Aparato Digestivo, Madrid, Spain

P502 Tumour necrosis factor antagonists are superior to anti-integrin and anti-IL-12/23 therapies for preventing postoperative recurrence in adult Crohn’s disease patients requiring postoperative therapy

ECCO'20 Vienna

Year: 2020
Authors:

T. Nakamura1, R. Shah2, M. Sachs3, S. Chang4, D. Hudesman4, B. Click5, J. Axelrad4

1New York University Medical Center, Medicine, New York, USA, 2Cleveland Clinic Medical Center, Medicine, Cleveland, USA, 3Karolinska, Clinical Epidemiology, Solna, Sweden, 4Gastroenterology and Hepatology, New York University Medical Center, New York, USA, 5Gastroenterology- Hepatology- and Nutrition, Cleveland Clinic Medical Center, Cleveland, USA

P503 Changes in clinical use of vedolizumab are driven by lower drug costs and are associated with better outcomes: a real-life single-centre Spanish experience

ECCO'20 Vienna

Year: 2020
Authors:

Y. Gonzalez Lama, M. Calvo, V. Matallana, I. Gonzalez-Partida, I. Omella, M.I. Vera

Department of Gastroenterology, University Hospital Puerta De Hierro, Majadahonda, Spain

P504 Remote cannabis-therapy management platform for IBD patients: performance assessment

ECCO'20 Vienna

Year: 2020
Authors:

G. Sweed1, C. Shapira2, T. Naftali3

1Clalit health care, Occupational Medicine, Haifa, Israel, 2Technion, Israel institute of technology, Haifa, Israel, 3Clalit health care, Gastroenterology, Kfar Saba, Israel

P505 Different failure rates after non-medical switching of 744 patients from adalimumab originator to 2 different adalimumab biosimilars at Cambridge University Hospitals, UK: real-world experience

ECCO'20 Vienna

Year: 2020
Authors:

D. Rosembert1, A. Malaviya2, J. How2, J. Tomlison3, F. Toh3, M. Roe1, A. Nightingale4, C. Garcia-Sueiro4, P. Herbert4, D. Jadon2, P. Norris3, J. Thomas3, J. Magsino4, A. Negoescu2, T. Raine4

1Department of Pharmacy, Cambridge University Hospitals, Cambridge, UK, 2Department of Rheumatology, Cambridge University Hospitals, Cambridge, UK, 3Department of Dermatology, Cambridge University Hospitals, Cambridge, UK, 4Department of Gastroenterology, Cambridge University Hospitals, Cambridge, UK

P506 Increased risk of anti-drug antibodies to a second anti-TNF in patients who developed antibodies to the first anti-TNF

ECCO'20 Vienna

Year: 2020
Authors:

H. Yanai1,2, S. Amir2, I. Avni Biron1,2, T. Tsadok Perets1,2, R. Shamir2,3, I. Dotan1,2, A. Assa2,3

1Rabin Medical Center, IBD Center- Division of Gastroenterology, Petah-Tikva, Israel, 2Tel Aviv University, Sackler Faculty of Medicine-, Tel Aviv, Israel, 3Schneider Children’s Medical Center, The Institute of Gastroenterology- Nutrition and Liver diseases, Petah Tikva, Israel

P507 Ustekinumab: Medium-term outcomes from a UK multicentre real-world cohort

ECCO'20 Vienna

Year: 2020
Authors:

R. Gadhok1, K. Fragkos2, S. Honap3, J. Hassan2, L. Whiteley2, A. Ibarra1, N. Burgess1, R. Vega2, E. Seward2, S. Mehta2, S. McCartney2, S. Bloom2, G. Parkes1, P. Irving3, J.O. Lindsay1, K.B. Kok1, F. Rahman2

1Gastroenterology, Royal London Hospital- Barts Health NHS Trust, London, UK, 2Gastroenterology, University College London Hospital NHS Trust, London, UK, 3Gastroenterology, Guys and St Thomas’ Hospital NHS Trust, London, UK

P508 Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study

ECCO'20 Vienna

Year: 2020
Authors:

L. Goessens1, J.F. Colombel2, A. Outtier3, M. Ferrante3, M. Truyens4, T. Lobaton4, F. Baert5, P. Bossuyt6, A. Cremer7, E. Macken8, B. Strubbe9, J.F. Rahier1

1CHU UCL Namur, Gastroenterology, Yvoir, Belgium, 2Icahn School of Medicine at Mount Sinai, Gastroenterology, New-York, USA, 3University Hospitals Leuven, Gastroenterology and Hepatology, Leuven, Belgium, 4University Hospital Gent, Gastroenterology, Gent, Belgium, 5AZ Delta, Gastroenterology, Roeselare, Belgium, 6Imelda General Hospital, Gastroenterology, Bonheiden, Belgium, 7Erasme University Hospital, Gastroenterology, Bruxelles, Belgium, 8University Hospital Antwerp, Gastroenterology, Edegem, Belgium, 9AZ Sint-Lucas, Gastroenterology, Gent, Belgium

P509 Vedolizumab levels in breast milk: Results from a prospective, postmarketing, milk-only lactation study in nursing mothers with inflammatory bowel disease

ECCO'20 Vienna

Year: 2020
Authors:

W. Sun1, B. Fennimore2, D.B. Beaulieu3, R. Arsenescu4, A. Stein5, J. Chen6, T. Lin7, S. McKnight8, M. Rosario9, R.A. Lirio10

1Takeda, Quantitative Clinical Pharmacology, Cambridge, USA, 2University of Colorado, Department of Medicine Gastroenterology, Aurora, USA, 3Vanderbilt University Medical Center, Vanderbilt Digestive Disease Center, Nashville, USA, 4Morristown Medical Center, AHS Hospital Corporate, Morristown, USA, 5Northwestern University, Division of Gastroenterology and Hepatology, Chicago, USA, 6Takeda, Statistics and Quantitative Sciences, Cambridge, USA, 7Certara, Integrated Drug Development, Princeton, USA, 8Takeda, Global Program Management, Cambridge, USA, 9Takeda, Clinical Pharmacology, Cambridge, USA, 10Takeda, Clinical Science, Cambridge, USA

P510 Dose escalation of subcutaneous vedolizumab in patients with ulcerative colitis: A post hoc analysis of the VISIBLE trial data

ECCO'20 Vienna

Year: 2020
Authors:

W. Sandborn1, D. Wolf2, G. D’haens3, J. Jansson4, J. Chen5, S. Uddin5, N. Candela6, K. Lasch6, K. Kisfalvi5

1University of California San Diego, Division of Gastroenterology, La Jolla, USA, 2Atlanta Gastroenterology Associates, Gastroenterology, Atlanta, USA, 3University of Amsterdam- Academic Medical Center, Gastroenterology, Amsterdam, The Netherlands, 4Takeda Development Center Americas Inc-, Gastroenterology, Cambridge, USA, 5Takeda Development Center Americas Inc., Gastroenterology, Cambridge, USA, 6US Medical Office- Takeda Pharmaceuticals USA Inc., Gastroenterology, Deerfield, USA

P511 Association of ustekinumab serum concentrations and clinical outcomes: results from the mUST-DECIDE trial

ECCO'20 Vienna

Year: 2020
Authors:

B. Bressler1, B. Sattin2, M.A. Williamson2, R. Khanna3, C.H. Seow4, D. Dajnowiec2, K. Karra2, L.L. Gao5, W. Afif6, mUST-Decide

1Department of Gastroenterology, University of British Columbia, Vancouver, Canada, 2Department of Medical Affairs, Janssen Canada, Toronto, Canada, 3Department of Epidemiology and Biostatistics, Western University, London, Canada, 4Department of Gastroenterology, University of Calgary Calgary, Canada, 5Research and Development- LLC, Janssen Inc., Spring House, USA, 6Inflammatory Bowel Disease Centre, McGill University Health Centre, Montreal, Canada

P512 Efficacy of tofacitinib for the treatment of moderate-to-severe ulcerative colitis: real-world data

ECCO'20 Vienna

Year: 2020
Authors:

Y. XIAO1, P.L. Lakatos2, R. Bourdages3, A. Bitton2, W. Afif2, R. Kohen2, M. Berberi3, T. Bessissow2

1Division of Internal Medicine, McGill University, Montreal, Canada, 2Division of Gastroenterology, McGill University, Montreal, Canada, 3Division of Gastroenterology, Hopital Hotel-Dieu de Lévis, Quebec City, Canada

P513 has been withdrawn

ECCO'20 Vienna

Year: 2020
P514 Does faecal diversion induce clinical response for Crohn’s disease of the colorectum?

ECCO'20 Vienna

Year: 2020
Authors:

A. Lightner1, H. Buhulaigah2, K. Zaghiyan2, P. Vaidya1, M. Regueiro1, P. Fleshner2

1Department of Colorectal Surgery, Cleveland Clinic, Cleveland, USA, 2Cedars-Sinai, Colon and Rectal Surgery, Cleveland- OH, USA